Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any cone dystrophy in which the cause of the disease is a mutation in the GUCA1A gene.
Features include sometimes findings: Macular atrophy. 5 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 1 | Macular atrophy |
Muscles | 1 | Macular atrophy |
GUCA1A encodes guanylate cyclase activator 1A (201 aa). Stimulates retinal guanylyl cyclase when free calcium ions concentration is low and inhibits guanylyl cyclase when free calcium ions concentration is elevated. Highest expression in Testis (52.1 TPM) and Brain Nucleus accumbens basal ganglia (18.0 TPM).
Cone dystrophy 3 is caused by mutations in the GUCA1A gene on chromosome 6.
The GUCA1A protein participates in GUCYs converts GTP to cGMP pathway.
GUCA1A is classified as a druggable target (Enzyme category) with score 26.1.
Genetic testing for GUCA1A is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for cone dystrophy 3 has been reported in the published literature.
No clinical trials have been registered for cone dystrophy 3.
29 publications have been identified in PubMed for cone dystrophy 3. Research spans Basic Science / Preclinical (34%), Case Report / Case Series (24%), and Review / Meta-Analysis (10%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 10 | 34% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about cone dystrophy 3
7 |
24% |
Research summaries | 3 | 10% |
Disease patterns and progression | 3 | 10% |
Other research | 2 | 7% |
Testing and diagnosis research | 2 | 7% |
New treatment approaches | 2 | 7% |
Varughese RS (2026). [PMID: 42044156](https://pubmed.ncbi.nlm.nih.gov/42044156/). *J Clin Endocrinol Metab*. [Other]
Warszawer Y (2026). [PMID: 41317340](https://pubmed.ncbi.nlm.nih.gov/41317340/). *Eur Neurol*. [Other]
Teixeira-Martins R (2026). [PMID: 41788630](https://pubmed.ncbi.nlm.nih.gov/41788630/). *Case reports in ophthalmology*. [Case Report / Case Series]
Chou JJ (2026). [PMID: 41954843](https://pubmed.ncbi.nlm.nih.gov/41954843/). *Doc Ophthalmol*. [Case Report / Case Series]
Lin S (2026). [PMID: 41720099](https://pubmed.ncbi.nlm.nih.gov/41720099/). *American journal of human genetics*. [Basic Science / Preclinical]
Luo Q (2025). [PMID: 40606666](https://pubmed.ncbi.nlm.nih.gov/40606666/). *Frontiers in genetics*. [Basic Science / Preclinical]
Wu C (2025). [PMID: 40414337](https://pubmed.ncbi.nlm.nih.gov/40414337/). *Experimental eye research*. [Basic Science / Preclinical]
Lobo R (2025). [PMID: 41312338](https://pubmed.ncbi.nlm.nih.gov/41312338/). *Case reports in ophthalmological medicine*. [Case Report / Case Series]
Allon G (2025). [PMID: 39969478](https://pubmed.ncbi.nlm.nih.gov/39969478/). *Investigative ophthalmology & visual science*. [Case Report / Case Series]
Wong WM (2025). [PMID: 40013354](https://pubmed.ncbi.nlm.nih.gov/40013354/). *Clinical & experimental ophthalmology*. [Review / Meta-Analysis]